SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:liu-131161"
 

Sökning: id:"swepub:oai:DiVA.org:liu-131161" > Efficacy and safety...

  • De Backer, OleCopenhagen University Hospital, Denmark (författare)

Efficacy and safety of the Lotus Valve System for treatment of patients with severe aortic valve stenosis and intermediate surgical risk: Results from the Nordic Lotus-TAVR registry

  • Artikel/kapitelEngelska2016

Förlag, utgivningsår, omfång ...

  • Elsevier,2016
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-131161
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-131161URI
  • https://doi.org/10.1016/j.ijcard.2016.05.072DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background: Transcatheter aortic valve replacement (TAVR) has becomean established therapeutic option for patients with symptomatic, severe aortic valve stenosis (AS) who are ineligible or at high risk for conventional valvular surgery. In Northwestern Europe, the TAVR technology is also increasingly used to treat patients with an intermediate risk profile. Methods and results: The study was designed as an independent Nordic multicenter registry of intermediate risk patients treated with the Lotus Valve System (Boston Scientific, MA, USA; N = 154). Valve Academic Research Consortium (VARC)-defined device success was obtained in 97.4%. A Lotus Valve was successfully implanted in all patients. There was no valve migration, embolization, ectopic valve deployment, or TAV-in-TAV deployment. The VARC-defined combined safety rate at 30 days was 92.2%, with a mortality rate of 1.9% and stroke rate of 3.2%. The clinical efficacy rate after 30 days was 91.6% - only one patient had moderate aortic regurgitation. When considering only those patients in the late experience group (N=79), the combined safety and clinical efficacy rates were 93.7% and 92.4%, respectively. The pacemaker implantation rate was 27.9% - this rate was 12.8% in case of a combined implantation depth amp;lt;4 mm and a device/annulus ratio amp;lt; 1.05. Conclusions: The present study demonstrates the efficacy and safety of the repositionable, retrievable Lotus Valve System in intermediate risk patients with AS. The VARC-defined device success rate was 97.4% with a 30-day patient safety and clinical efficacy rate of more than 90%. Less than moderate aortic regurgitation was obtained in 99.4% of patients. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Gotberg, MatthiasSkåne University Hospital, Sweden (författare)
  • Ihlberg, LeoHelsinki University Hospital, Finland (författare)
  • Packer, ErikHaukeland Hospital, Norway (författare)
  • Savontaus, MikkoTurku University Hospital, Finland (författare)
  • Nielsen, Niels ErikLinköpings universitet,Avdelningen för kardiovaskulär medicin,Hälsouniversitetet,Region Östergötland, Kardiologiska kliniken US(Swepub:liu)nieni36 (författare)
  • Jorgensen, Troels H.Copenhagen University Hospital, Denmark (författare)
  • Nykanen, AnttiHelsinki University Hospital, Finland (författare)
  • Baranowski, JacekLinköpings universitet,Avdelningen för kardiovaskulär medicin,Medicinska fakulteten,Region Östergötland, Fysiologiska kliniken US (författare)
  • Niemela, MattiOulu University Hospital, Finland (författare)
  • Eskola, MarkkuTampere University Hospital, Finland (författare)
  • Bjursten, HenrikSkåne University Hospital, Sweden (författare)
  • Söndergaard, LarsCopenhagen University Hospital, Denmark (författare)
  • Copenhagen University Hospital, DenmarkSkåne University Hospital, Sweden (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:International Journal of Cardiology: Elsevier219, s. 92-970167-52731874-1754

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy